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Lately, microdeletions of the 22q region, responsible for DiGeorge syndrome or velocardiofacial syndrome, have been increas-
ingly related to neuropsychiatric disorders including schizophrenia and bipolar disorder. These manifestations seem to be related to
certain genes located in the hemideleted region such as the proline dehydrogenase (PRODH) and the catechol-o-methyltransferase
(COMT) genes.
We describe a teenager who started his adolescent psychiatric care presenting cognitive impairment, irritable mood and aggres-
sive behaviour with schizophrenia-like symptoms that scored 153 in the Positive and Negative Symptoms Scale (PANSS)
assessment.
Worsening of symptoms when the patient was treated with valproic acid, and plasma aminoacids showing an increase in alanine
and proline, suggested a mitochondrial involvement of the proline metabolic pathway. Mild dysmorphic features also suggested a
possible 22q11 deletion syndrome that was conﬁrmed. A mutation for Hyperprolinemia type I was also detected.
Knowledge of the correct diagnosis was crucial for an adequate treatment.
 2017 The Japanese Society of Child Neurology. Published by Elsevier B.V. All rights reserved.
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Patients with a 22q11.2 deletion syndrome, usually
present developmental delay, poor growth, distinctive
facial features, microcephaly, cleft palate, heart abnor-
malities and immunological problems. Recent studieshttp://dx.doi.org/10.1016/j.braindev.2017.01.008
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toms, depression, anxiety and bipolar disorder [1]. The
loss of one copy of susceptible genes located in the
22q11del region such as the COMT gene, an intracellu-
lar postsynaptic enzyme that modulates dopamine
clearance, and PRODH gene may ultimately lead to a
psychiatric dysfunction [2].
The PRODH gene encodes proline dehydrogenase or
proline oxidase (POX), a mitochondrial enzyme involved
in proline catabolic pathway converting proline tolsevier B.V. All rights reserved.
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Fig. 1. Proline metabolism. P5C: pyrroline-5-carboxylate; POX: proline oxidase; HPI: Hyperprolinemia type I; HPII: Hyperprolinemia type II.
2 M. Duarte et al. / Brain & Development xxx (2017) xxx–xxxdelta-1-pyrroline-5-carboxylate (D1-P5C) [3]. Proline
plays a role in urea cycle where it can be endogenously
synthesized (Fig. 1). Several disorders in proline metabo-
lism have been identiﬁed, such as deﬁciency of POX or
Hyperprolinemia type I (HPI) and deﬁciency of the activ-
ity of D1-P5C dehydrogenase or Hyperprolinemia type II
(HPII). Both rare diseases, inherited as autosomal reces-
sive disorders and characterized biochemically by high
proline levels [4–6]. Although the neuropsychiatric phe-
notype has been primarily associated with HPII [6,7], a
growing number of patients with these features, in partic-
ular schizophrenia, have been documented for HPI [8].
2. Case report
We describe a 17-year-old male patient, whose rele-
vant family history includes only a maternal great-
uncle with schizophrenia.
He presented mild hypotonia in infancy and later on
diﬃculties in motor coordination (but walking indepen-
dently at the age of 14 months) and language delay (ﬁrst
words at 3 years and joining words at the age of 4) requir-
ing physiotherapy and speech therapy with subsequent
learning diﬃculties.Karyotype and fragile-X studies were
normal. As he grew older, he started showing some man-
ifestations in daily life suggesting obsessive behaviour
leading sometimes to bullying and refusal to go to school.
When he had his ﬁrst observation in the Psychiatric
Outpatient Unit at the age of 15, he presented compul-
sive and obsessive symptoms, anxiety, a mixed depres-
sive/irritable mood and aggressive behaviour. The
speech was impaired, with some diﬃculty in articulatingPlease cite this article in press as: Duarte M et al. Hyperprolinemia as a clu
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Wechsler Intelligence Scale for Children (WISC) III was
performed and scored medium low in the Verbal IQ and
very low in the Non-Verbal IQ.
Themood, irritability, anxiety anddisruptedbehaviour
improved with the prescription of quetiapine but over the
following months he revealed a disorganized behaviour
with paranoid, reference and grandiose delusions.
When admitted to the Inpatient Unit at the age of 17,
he appeared to be restless, tense, with an irritable mood
and auditory hallucinations. The Positive and Negative
Symptoms Scale (PANSS) performed at admission
scored 153: 33 for Positive Symptoms, 45 for Negative
Symptoms and 75 for General Symptoms Subscale. Rou-
tine blood tests, including calcemia and investigations for
psychosis were within normal range. BrainMRI revealed
only non-speciﬁc ﬁndings and EEG was unremarkable.
Olanzapine caused partial improvement of his
psychotic symptoms and aggressive behaviour but he
maintained an irritable mood. Valproic acid was then
added but during the increase to therapeutic values, he
deteriorated (aggressive behaviour, long periods of iso-
lation and drowsiness) leading to the discontinuation
of this drug. As liver function tests showed normal
values, a valproate intoxication was excluded and a
mitochondrial disorder was suspected.
Treatment with lithium and olanzapine led to
improvement in behaviour and psychotic symptoms.
Further investigations revealed normal lactic acid
and ammonia values, elevation in proline (511 and
403 lM/L; RV:51–271 lM/L) and alanine (623.7 and
594 lM/L; RV < 400 lM/L) levels. Urinary organice in the diagnosis of a patient with psychiatric manifestations. Brain
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to the diagnosis of a possible HPI.
Considering slightly dysmorphic features (low set ears
and hirsute eyebrows) despite normal growth and no
major abnormalities and the knowledge that HPI is
located on chromosome 22q11, a multiplex ligation-
dependent probe ampliﬁcation (MLPA) test was per-
formed using the probemix P250-B1 (MRC-Holland,
Amsterdam,TheNetherlands) that conﬁrmed a heterozy-
gous 22q11 deletion from gene CLTCL1 to gene LZTR1.
Another probemix, P324-A2 (MRC-Holland, Amster-
dam, The Netherlands) that contains three probes for
PRODH gene conﬁrmed this deletion spanning from
17,298,536 to 19,779,435 bp (hg18), comprising both the
PRODH and the COMT genes. Cardiac evaluation was
normal.
The high proline levels are not usually observed in
patients with 22q11 deletions and as HPI and HPII
are autosomal recessive disorders, molecular studies
for the investigation of the PRODH gene, were per-
formed and revealed a p.L289M (c.1865T > A) muta-
tion in heterozygosity.
3. Discussion
Most patients with the 22q11 deletion have congenital
abnormalities which is not the case of this patient that
manifests solely mild dysmorphic features. As described
previously our patient had hypotonia, psychomotor and
language delay but unlike most of the described patients
could speak ﬂuently and attended normal schooling [9].
Also, our case had lower values of proline when com-
pared with a similar case described (930–1000 lmol/L
[9] and didn’t had any cardiac abnormalities.
Nevertheless the cognitive and psychological impair-
ment he presents are not so well known. Most genes in
chromosome loci 22q11 are expressed in the brain and
hypothetically related to executive functions [2,3].
A metabolic disorder was suspected due to the pres-
ence of the cognitive delay associated with psychotic fea-
tures as well as deterioration after the initiation of
valproic acid as normal liver function excluded toxicity.
Valproate metabolization occurs primarily in the liver
mitochondria, and thus should be avoided in cases of
mitochondrial disorders, as it may stress vital pathways
that intensify the genetic damage [10].
The knowledge that HPI is caused by mutations in
the chromosome 22q11 led to further investigations that
conﬁrmed the 22q11 deletion. Nevertheless, considering
the moderate elevation of proline and that HPI is auto-
somal recessive, these ﬁndings could not be explained
solely by the detected deletion. Complementary investi-
gations showed heterozygous p.L289M (c.1865T > A)
mutation in the PRODH gene already described in schi-
zophrenic patients and that may lead to a decrease of a
30% activity of POX [11,12].Please cite this article in press as: Duarte M et al. Hyperprolinemia as a clu
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region and a heterozygous mutation on the PRODH
gene on the other allele may somehow result in a com-
posed heterozygosity of this gene and have a moderate
eﬀect on POX activity [3,12].
This decreased activity could inﬂuence the proline/
glutamate levels related with apoptosis in selected neu-
rons [2,3]. It is possible that the overall phenotype of
cognitive and psychiatric anomalies could be a conse-
quence of several genes aﬀected in this locus deletion
or their interaction.
This case is also clear evidence that knowing the aeti-
ology of psychiatric manifestations is important in the
management of patients preventing use of deleterious
drugs or creating new therapeutic approaches. It also
shows that it may be diﬃcult to diagnose chromosomal
abnormalities in patients with no clear malformations
and mild dysmorphic features as the pleiotropism of
the gene/deletion could probably lead to diﬀerent
phenotypes.References
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